<http://webisa.webdatacommons.org/161423640>	<http://www.w3.org/1999/02/22-rdf-syntax-ns#type>	<http://www.w3.org/ns/prov#Entity> .
<http://webisa.webdatacommons.org/prov/133358274>	<http://www.w3.org/ns/prov#wasDerivedFrom>	<http://webisa.webdatacommons.org/161423640> .
<http://webisa.webdatacommons.org/prov/478974734>	<http://www.w3.org/ns/prov#wasDerivedFrom>	<http://webisa.webdatacommons.org/161423640> .
<http://webisa.webdatacommons.org/161423640>	<http://www.w3.org/ns/prov#wasQuotedFrom>	<bio-medicine.org> .
<http://webisa.webdatacommons.org/161423640>	<http://www.w3.org/ns/prov#value>	"Statements herein relating to future development results and performance, conditions or strategies and other matters, including expectations regarding the strategic partnership with Cadila, the establishment of a manufacturing facility in India and the development and commercialization of VLP vaccines in India, are forward-looking statements within the meaning of the Private Securities Litigation" .